Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study.

Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Fléchon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Moreno BH, Beaumont JL, Purnajo I, McManus S, Powles T

Open source

DOI: 10.1016/s1470-2045(25)00158-5
Published: 2025 Jun
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-25-00158-5,
  title = {Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study.},
  author = {Gupta S and Loriot Y and Van der Heijden MS and Bedke J and Valderrama BP and Kikuchi E and Fléchon A and Petrylak D and De Santis M and Galsky MD and Lee JL and Swami U and Sridhar SS and De Giorgi U and Wright P and Shih V and Lu YT and Guan X and Dillon R and Shetty A and Moreno BH and Beaumont JL and Purnajo I and McManus S and Powles T},
  year = {2025},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(25)00158-5},
  url = {https://doi.org/10.1016/s1470-2045(25)00158-5}
}

RIS

TY  - JOUR
TI  - Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study.
AU  - Gupta S
AU  - Loriot Y
AU  - Van der Heijden MS
AU  - Bedke J
AU  - Valderrama BP
AU  - Kikuchi E
AU  - Fléchon A
AU  - Petrylak D
AU  - De Santis M
AU  - Galsky MD
AU  - Lee JL
AU  - Swami U
AU  - Sridhar SS
AU  - De Giorgi U
AU  - Wright P
AU  - Shih V
AU  - Lu YT
AU  - Guan X
AU  - Dillon R
AU  - Shetty A
AU  - Moreno BH
AU  - Beaumont JL
AU  - Purnajo I
AU  - McManus S
AU  - Powles T
PY  - 2025
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(25)00158-5
UR  - https://doi.org/10.1016/s1470-2045(25)00158-5
ER  -

APA

S, G., Y, L., MS, V. D. H., J, B., BP, V., E, K., A, F., D, P., M, D. S., MD, G., JL, L., U, S., SS, S., U, D. G., P, W., V, S., YT, L., X, G., R, D., A, S., BH, M., JL, B., I, P., S, M., & T, P. (2025). Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(25)00158-5

Source records

pubmed · retrieved 2026-11-10T19:55:39.881Z